Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity.

Creator(s)

Ryan S. Funk
Nasreen Talib, Children's Mercy HospitalFollow
Kanecia O. Zimmerman
Leon van Haandel
Mara L. Becker

Document Type

Article

Publication Date

6-1-2020

Identifier

DOI: 10.1016/j.jpeds.2020.01.032

Abstract

Methotrexate is used to treat autoimmune and oncologic diseases in children with Down syndrome. However, increased methotrexate-related toxicity is reported in this population. We evaluated differences in the concentrations and distribution of erythrocyte folates in children with Down syndrome as a potential basis for this enhanced toxicity.

Journal Title

The Journal of pediatrics

Volume

221

First Page

235

Last Page

239

PubMed ID

32111377

Keywords

Down syndrome; folates; pediatrics; precision medicine; toxicity

Comments

Grant support

• K23 HD091398/HD/NICHD NIH HHS/United States
• KL2 TR002367/TR/NCATS NIH HHS/United States
• L40 AR074291/AR/NIAMS NIH HHS/United States
• P20 GM130423/GM/NIGMS NIH HHS/United States

Recommended Citation

Funk RS, Talib NJ, Zimmerman KO, van Haandel L, Becker ML. Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity. J Pediatr. 2020;221:235-239. doi:10.1016/j.jpeds.2020.01.032